New indication for Xolair approved by the European Commission for treatment in chronic spontaneous urticaria patients

Novartis has announced that the European Commission (EC) has approved the use of Xolair® as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients, who do not respond to the current mainstay of therapy, H1 antihistamines. The approved dose in CSU is 300 mg administered by subcutaneous injection once every four weeks. Prescribers are advised to periodically reassess the need for continued therapy. Clinical trial experience of treatment beyond six months in this indication is limited.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Dermatology Source Type: news